Press Releases Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Market Closed - Nyse Other stock markets 04:00:02 2024-04-29 pm EDT			5-day change	1st Jan Change
15.63 ^USD	+0.51%		+0.84%	-18.17%

Mar. 12	Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Feb. 29	Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting	Apr. 24	BU
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update	Apr. 23	BU
Arcus Biosciences Announces New Employment Inducement Grants	Apr. 09	BU
Arcus Biosciences Announces New Employment Inducement Grants	Mar. 26	BU
Arcus Biosciences Announces New Employment Inducement Grants	Mar. 11	BU
Arcus Biosciences to Participate in Two Upcoming Investor Conferences	Feb. 28	BU
Arcus Biosciences Announces New Employment Inducement Grants	Feb. 27	BU
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update	Feb. 21	BU
Arcus Biosciences Announces New Employment Inducement Grants	Feb. 09	BU
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates	Feb. 07	BU
Gilead and Arcus Announce Amended Collaboration and Equity Investment	Jan. 29	BU
Gilead and Arcus Announce Amended Collaboration and Equity Investment	Jan. 29	BU
Arcus Biosciences Announces New Employment Inducement Grants	Jan. 26	BU
Arcus Biosciences, Inc. - Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer	Jan. 17	AQ
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer	Jan. 16	BU
Arcus Biosciences Announces New Employment Inducement Grants	Dec. 11	BU
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma	Dec. 04	BU
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma	Dec. 04	BU
Arcus Biosciences Announces New Employment Inducement Grants	Nov. 27	BU
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference	Nov. 14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Press Releases

Filters